

FORM PTO 1449 (modified)

Atty. Docket No.
X-12553Serial No
09/856,451

RECEIVED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONApplicants
John Michael Beals, et al.

OCT 11 2001

Filing Date
May 22, 2001Group
16001653

TECH CENTER 1600/2901

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub- class	Filing Date If Appropriate
Smu	AA	5,252,714	10/12/93	J. Milton Harris, et al.	530	391.9	11/28/90
Smu	AB	4,002,531	01/11/77	Garfield P. Royer	195	68	01/22/76
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub- class	Translation	
							yes	no
Smu	BA	WO95/06058	02.03.95	PCT				
	BB							
	BC							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Smu	CA		G.E. Francis, et al., <i>International Journal of Hematology</i> , PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques, Vol. 68(1), pages 1-18, 1998.					
	CB		C. Delgado, et al., <i>Pharmaceutical Sciences</i> , Polymer-derivatized Proteins: Analytical and Preparative Problems, Vol. 3(1), pages 59-66, 1997.					
	CC		G.E. Francis, et al., <i>Journal of Drug Targeting</i> , Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting, Vol. 3(5), pages 321-340, 1996.					
	CD		Gillian E. Francis, <i>Innovations in Pharmaceutical Technology</i> , PEGylation technology, pages 41-45.					
	CE		Farooq Malik, <i>Open University, Volume 58/01-C of Dissertation Abstracts International</i> , Construction and characterization of polyethylene glycol-modified cytokines (monomethoxypolyethylene glycol), page 208, 1993.					
	CF		Cristina Delgado, et al., <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , The uses and Properties of PEG-Linked Proteins, Vol. 9(3,4), pages 249-304, 1992.					
	CG		Gillian E. Francis, et al., <i>Stability of Protein Pharmaceuticals, Part B: In vivo Pathways of Degradation and Strategies for Protein Stabilization</i> , eds, Ahern TJ and Manning MC, Plenum Press, New York, PEG-Modified Proteins, 1992.					

EXAMINER

Lynne M. Noakes


DATE CONSIDERED

12/30/2005

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

OCT 11 2001

~~TECH CENTER 1600/29~~

FORM PTO 1449 (modified)		Atty. Docket No. X-12553		Serial No 09/856,451	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant John Michael Beals, et al.		OCT 1 TECH CENTER	
		Filing Date May 22, 2001		Group 1600 1653	
	CH		Gillian E. Francis, Focus on Growth Factors, Protein modification and fusion proteins, Vol. 3, pages 4-10, 1992.		
	CI		Mendel Friedman, et al., International Journal Peptide Protein Research, REDUCTIVE ALKYLATION OF PROTEINS WITH AROMATIC ALDEHYDES AND SODIUM CYANOBOROHYDRIDE, Vol. 6(3), pages 183-185, 1974.		
	CJ		Rashid S. Syed, et al., Nature, Efficiency of signalling through cytokine receptors depends critically on receptor orientation, Vol. 395(6701), pages 511-516, October 1, 1998.		
	CK		Janet C. Cheetham, et al., Nature Structural Biology, NMR structure of human erythropoietin and a comparison with its receptor bound conformation, Vol. 5(10), pages 861-866, October 1998.		
	CL				
	CM				
	CN				
	CO				
	CP				
	CQ				
	CR				
	EXAMINER		DATE CONSIDERED		
Suzanne M. Moakes		12/30/2005			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					